MedTrace Logo

IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.

NCT00091507 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 911

Last updated 2016-03-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the impact of pharmacological myocardial metabolic support, in the form of intravenous (IV) glucose, insulin and potassium (GIK), for the treatment of patients with threatened or established acute myocardial infarction (AMI).

Conditions

Interventions

DRUG

GIK

Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.

DRUG

Placebo

Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Tufts Medical Center

    lead OTHER

Principal Investigators

  • Harry Selker, MD, MSPH · Tufts Medical Center, Trial Coordinating Center

  • Ralph D'Agostino, PhD · Tufts Medical Center, Data Coordinating Center

  • James Udelson, MD · Tufts Medical Center, LV Core Lab

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2011-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00091507 on ClinicalTrials.gov